Patents by Inventor Nobuaki ADACHI

Nobuaki ADACHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,3-benzodioxole derivative
    Patent number: 10954219
    Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1, 3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: March 23, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Osamu Kanno, Jun Watanabe, Takao Horiuchi, Akira Nakao, Keisuke Suzuki, Tomonori Yamasaki, Nobuaki Adachi, Daisuke Honma, Yoshito Hamada
  • Agent for treating and/or preventing adult T cell leukemia/lymphoma
    Patent number: 10434091
    Abstract: The present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing, as an active ingredient, 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: October 8, 2019
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, THE UNIVERSITY OF TOKYO
    Inventors: Toshiki Watanabe, Makoto Yamagishi, Osamu Kanno, Jun Watanabe, Nobuaki Adachi, Daisuke Honma, Yoshito Hamada
  • 1,3-BENZODIOXOLE DERIVATIVE
    Publication number: 20180282313
    Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).
    Type: Application
    Filed: June 7, 2018
    Publication date: October 4, 2018
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Osamu KANNO, Jun WATANABE, Takao HORIUCHI, Akira NAKAO, Keisuke SUZUKI, Tomonori YAMASAKI, Nobuaki ADACHI, Daisuke HONMA, Yoshito HAMADA
  • THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA
    Publication number: 20180200238
    Abstract: The present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing, as an active ingredient, 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 29, 2016
    Publication date: July 19, 2018
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, THE UNIVERSITY OF TOKYO
    Inventors: Toshiki WATANABE, Makoto YAMAGISHI, Osamu KANNO, Jun WATANABE, Nobuaki ADACHI, Daisuke HONMA, Yoshito HAMADA
  • 1,3-benzodioxole derivative
    Patent number: 10017500
    Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: July 10, 2018
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Osamu Kanno, Jun Watanabe, Takao Horiuchi, Akira Nakao, Keisuke Suzuki, Tomonori Yamasaki, Nobuaki Adachi, Daisuke Honma, Yoshito Hamada
  • 1,3-BENZODIOXOLE DERIVATIVE
    Publication number: 20170073335
    Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).
    Type: Application
    Filed: March 16, 2015
    Publication date: March 16, 2017
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Osamu KANNO, Jun WATANABE, Takao HORIUCHI, Akira NAKAO, Keisuke SUZUKI, Tomonori YAMASAKI, Nobuaki ADACHI, Daisuke HONMA, Yoshito HAMADA